ALAMAB THERAPEUTICS INC.
First-in-class monoclonal antibody therapeutics
- Sector
- Biotech
- Headquarters
- PRINCETON, NJ
- Founded
- 2017
- Latest Form D
- $11.8M, Aug 2017
- Total capital
- $11.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $11.8M
- 1 Form D · last Aug 2017
- 111 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 27 pending · first 2024
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$11.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- YANFENG ZHANGResearcherExecutive OfficerLinked by 4 patents
- JEAN X. JIANGDirectorNamed in SEC Form D filings
- JUMIN X. SUNDirectorNamed in SEC Form D filings
- QINGXI WANGExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 31- PendingMethod Of Treating Neurological DisorderUSPTOApplication 19549989
- PendingMethod Of Treating Bone CancersUSPTOApplication 19217871
- PendingAnti-connexin Antibody FormulationsUSPTOApplication 19235455
Show all 31 patent records
- Method Of Treating Neurological DisorderSep 3, 2026 · Application 19549989Pending
- Method Of Treating Bone CancersApr 16, 2026 · Application 19217871Pending
- Anti-connexin Antibody FormulationsFeb 19, 2026 · Application 19235455Pending
- Connexin 43 Antibodies And Use ThereofSep 18, 2025 · Application 19019170Pending
- Connexin 43 Antibodies And Use ThereofJul 17, 2025 · Application 18955222Pending
- Anti-connexin Antibody FormulationsJul 15, 2025 · US 12,358,981Granted
- Method Of Treating StrokeFeb 20, 2025 · Application 18803013Pending
- Connexin 43 Antibodies And Use ThereofFeb 18, 2025 · US 12,227,561Granted
- Connexin 43 Antibodies And Use ThereofJan 7, 2025 · US 12,187,794Granted
- Method Of Treating OsteoarthritisJan 2, 2025 · Application 18757078Pending
- Method Of Treating Bone CancersNov 28, 2024 · Application 18673081Pending
- Anti-connexin Antibody FormulationsSep 19, 2024 · Application 18415511Pending
- Anti-connexin Antibody FormulationsFeb 27, 2024 · US 11,912,764Granted
- Anti-connexin Antibody FormulationsApplication 62909267Pending
- Method Of Treating Neurological DisorderApplication PCTUS2026016669Pending
- Method Of Treating Neurological DisorderApplication 63765394Pending
- Connexin 43 Antibodies And Use ThereofApplication PCTUS2019025363Pending
- Connexin 43 Antibodies And Use ThereofApplication 62800869Pending
- Connexin 43 Antibodies And Use ThereofApplication 62651668Pending
- Method Of Treating Bone CancersApplication PCTUS2025030838Pending
- Method Of Treating StrokeApplication PCTUS2024042110Pending
- Method Of Treating OsteoarthritisApplication PCTUS2024035862Pending
- Method Of Treating Bone CancersApplication 63651826Pending
- Method Of Treating Bone CancersApplication PCTUS2024030843Pending
- Method Of Treating StrokeApplication 63519465Pending
- Method Of Treating OsteoarthritisApplication 63511563Pending
- Method Of Treating Bone CancersApplication 63504162Pending
- Anti-connexin Antibody FormulationsApplication PCTUS2021044043Pending
- Anto-connexin Antibody FormulationsApplication PCTUS2020054036Pending
- Anti-connexin Antibody FormulationsApplication 63059502Pending
- Connexin 43 Antibodies And Use ThereofApplication PCTUS2020016606Pending
Related companies, and why
- Cristcot LLCSimilar federal contract value in Biotech · null in contracts
- Angiex, Inc.Similar federal contract value in Biotech · null in contracts
- SpringWorks TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Alkahest, Inc.Similar federal contract value in Biotech · null in contracts
- Evercrisp Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Intrommune Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .